Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
In the last decade, optimized treatment for non-small cell lung cancer had lead to improved prognosis, but the overall survival is still very short. To further understand the molecular basis of the disease we have to identify biomarkers related to survival. Here we present the development of an online tool suitable for the real-time meta-analysis of published lung cancer microarray datasets to identify biomarkers related to survival. We searched the caBIG, GEO and TCGA repositories to identify samples with published gene expression data and survival information. Univariate and multivariate Cox regression analysis, Kaplan-Meier survival plot with hazard ratio and logrank P value are calculated and plotted in R. The complete analysis tool can be accessed online at: www.kmplot.com/lung. All together 1,715 samples of ten independent datasets were integrated into the system. As a demonstration, we used the tool to validate 21 previously published survival associated biomarkers. Of these, survival was best predicted by CDK1 (p<1E-16), CD24 (p<1E-16) and CADM1 (p = 7E-12) in adenocarcinomas and by CCNE1 (p = 2.3E-09) and VEGF (p = 3.3E-10) in all NSCLC patients. Additional genes significantly correlated to survival include RAD51, CDKN2A, OPN, EZH2, ANXA3, ADAM28 and ERCC1. In summary, we established an integrated database and an online tool capable of uni- and multivariate analysis for in silico validation of new biomarker candidates in non-small cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642 · cited 1×
“A previous meta-analysis of all the trials investigating chemotherapy benefit demonstrated a 5% improvement in overall survival [28].”
MethodBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025 · cited 1×
“While numerous individual genes associated with survival have been published in the last thirty years, new microarray-based multigene molecular prognostic models using genomic signatures have only emerged in the last ten years [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19].”
BackgroundDirector's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma (2008) · Nature Medicine · doi:10.1038/nm.1790 · Cited by 1,190
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9844 · Cited by 758
Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
Hou, J., Aerts, J., den Hamer, B., van IJcken, W., den Bakker, M., Riegman, P., van der Leest, C., van der Spek, P., Foekens, J. A., Hoogsteden, H. C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010312 · Cited by 755
Cited by
Chromosomal instability drives metastasis through a cytosolic DNA response
Bakhoum, S. F., Ngo, B., Laughney, A. M., Cavallo, J.-A., Murphy, C. J., Ly, P., Shah, P., Sriram, R. K., Watkins, T. B. K., Taunk, N. K., et al. (2018) · Nature · doi:10.1038/nature25432 · Cited by 1,593
Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H. D., Krishnan, I., Maroni, G., Meyerovitz, C. V., Kerwin, C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.009 · Cited by 1,475
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
cGAS is essential for cellular senescence
Yang, H., Wang, H., Ren, J., Chen, Q., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705499114 · Cited by 1,009
Szász, A. M., Lánczky, A., Nagy, Á., Förster, S., Hark, K., Green, J. E., Boussioutas, A., Busuttil, R., Szabó, A., & Győrffy, B. (2016) · Oncotarget · doi:10.18632/oncotarget.10337 · Cited by 988
Self-citationMa, J., Yang, F., Zhou, C., Liu, F., Yuan, J., Wang, F., Wang, T., Xu, Q., Zhou, W., & Sun, S. (2017) · Hepatology · doi:10.1002/hep.28885 · Cited by 912
Lánczky, A., Nagy, Á., Bottai, G., Munkácsy, G., Szabó, A., Santarpia, L., & Győrffy, B. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4013-7 · Cited by 768
Self-citationLee, K.-M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sánchez, V., Sanders, M. E., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.009 · Cited by 650
OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs
Anaya, J. (2016) · PeerJ Computer Science · doi:10.7717/peerj-cs.67 · Cited by 639
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Stopa, N., Krebs, J. E., & Shechter, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1847-9 · Cited by 513
Lin, X., Chai, G., Wu, Y., Li, J., Chen, F., Liu, J., Luo, G., Tauler, J., Du, J., Lin, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09865-9 · Cited by 510
RetractedRegenerative lineages and immune-mediated pruning in lung cancer metastasis
Laughney, A. M., Hu, J., Campbell, N. R., Bakhoum, S. F., Setty, M., Lavallée, V.-P., Xie, Y., Masilionis, I., Carr, A. J., Kottapalli, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0750-6 · Cited by 471
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution
Marjanovic, N. D., Hofree, M., Chan, J. E., Canner, D., Wu, K., Trakala, M., Hartmann, G. G., Smith, O. C., Kim, J. Y., Evans, K. V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.012 · Cited by 405
Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity
Yang, H., Xia, L., Chen, J., Zhang, S., Martin, V., Li, Q., Lin, S., Chen, J., Calmette, J., Lu, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0566-4 · Cited by 379
YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression
Shi, Y., Fan, S., Wu, M., Zuo, Z., Li, X., Jiang, L., Shen, Q., Xu, P., Zeng, L., Zhou, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12801-6 · Cited by 363
Győrffy, B. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16257 · Cited by 361
Self-citationN6-methyladenosine regulates glycolysis of cancer cells through PDK4
Li, Z., Peng, Y., Li, J., Chen, Z., Chen, F., Tu, J., Lin, S., & Wang, H. (2020) · Nature Communications · doi:10.1038/s41467-020-16306-5 · Cited by 323
Inhibitors of Protein Methyltransferases and Demethylases
Kaniskan, H. Ü., Martini, M. L., & Jin, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 297
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress
Liu, X., Xiao, Z.-D., Han, L., Zhang, J., Lee, S.-W., Wang, W., Lee, H., Zhuang, L., Chen, J., Lin, H.-K., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3328 · Cited by 288
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 287
ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis
Dey, S., Sayers, C. M., Verginadis, I. I., Lehman, S. L., Cheng, Y., Cerniglia, G. J., Tuttle, S. W., Feldman, M. D., Zhang, P. J. L., Fuchs, S. Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78031 · Cited by 282
Wu, J., Li, L., Zhang, H., Zhao, Y., Zhang, H., Wu, S., & Xu, B. (2021) · Oncogene · doi:10.1038/s41388-021-01853-y · Cited by 254
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.005 · Cited by 243
Xiang, L., Mou, J., Shao, B., Wei, Y., Liang, H., Takano, N., Semenza, G. L., & Xie, G. (2019) · Cell Death & Disease · doi:10.1038/s41419-018-1291-5 · Cited by 223
Zhang, H., Ramakrishnan, S. K., Triner, D., Centofanti, B., Maitra, D., Győrffy, B., Sebolt-Leopold, J. S., Dame, M. K., Varani, J., Brenner, D. E., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aac5418 · Cited by 196
Self-citationMechanosensitive ion channels push cancer progression
Pethő, Z., Najder, K., Bulk, E., & Schwab, A. (2019) · Cell Calcium · doi:10.1016/j.ceca.2019.03.007 · Cited by 125
Tang, H., Zeng, R., He, E., Zhang, I., Ding, C., & Zhang, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00085 · Cited by 120
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119
“gov/docs/publications/tcga/?]) for breast, ovarian, lung, gastric, and liver cancer (35) — was used to generate Kaplan-Meier survival statistics for patients with triple-negative basal-type breast carcinomas (n = 186), serous ovarian carcinomas (n = 1,001), and NSCLC (n = 1,926).”
BackgroundMethodShinde, A., Hardy, S. D., Kim, D., Akhand, S. S., Jolly, M. K., Wang, W.-H., Anderson, J. C., Khodadadi, R. B., Brown, W. S., George, J. T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2636 · Cited by 115
NOTCH-mediated non-cell autonomous regulation of chromatin structure during senescence
Parry, A. J., Hoare, M., Bihary, D., Hänsel-Hertsch, R., Smith, S., Tomimatsu, K., Mannion, E., Smith, A., D’Santos, P., Russell, I. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04283-9 · Cited by 102
Garg, A. D., Elsen, S., Krysko, D. V., Vandenabeele, P., de Witte, P., & Agostinis, P. (2015) · Oncotarget · doi:10.18632/oncotarget.4754 · Cited by 87
Huang, Z., Sun, Z., Zhang, X., Niu, K., Wang, Y., Zheng, J., Li, H., & Liu, Y. (2019) · Bioscience Reports · doi:10.1042/bsr20181679 · Cited by 82
High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer
Zhu, J., Ma, J., Wang, X., Ma, T., Zhang, S., Wang, W., Zhou, X., & Shi, J. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.003 · Cited by 75
“Because the PHGDH expression was significantly increased in NSCLC at both mRNA and protein levels, we further explored the effects of PHGDH mRNA expression levels on the survival by making use of online big data [17].”
MethodMASTL overexpression promotes chromosome instability and metastasis in breast cancer
Rogers, S., McCloy, R. A., Parker, B. L., Gallego-Ortega, D., Law, A. M. K., Chin, V. T., Conway, J. R. W., Fey, D., Millar, E. K. A., O’Toole, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0295-z · Cited by 67
“online Kaplan–Meier plotter tool (KMPlot) [18], we performed univariate analysis of MASTL expression on 1764 breast cancer patients.”
MethodA positive feedback loop of IL-17B-IL-17RB activates ERK/β-catenin to promote lung cancer metastasis
Yang, Y.-F., Lee, Y.-C., Lo, S., Chung, Y.-N., Hsieh, Y.-C., Chiu, W.-C., & Yuan, S.-S. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.037 · Cited by 52
The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer
Feng, A., Tu, Z., & Yin, B. (2016) · Oncotarget · doi:10.18632/oncotarget.7050 · Cited by 57
“com/oncotarget samples using the online KM-Potter tool [37].”
Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC
Lee, J.-S., Kang, J. H., Lee, S.-H., Hong, D., Son, J., Hong, K. M., Song, J., & Kim, S.-Y. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.404 · Cited by 56
Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0479-6 · Cited by 55
Yu, C., Hou, L., Cui, H., Zhang, L., Tan, X., Leng, X., & Li, Y. (2018) · Future Oncology · doi:10.2217/fon-2018-0177 · Cited by 52
Prognostic value of the mRNA expression of members of the HSP90 family in non‑small cell lung cancer
Liu, K., Kang, M., Li, J., Qin, W., & Wang, R. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7228 · Cited by 47
Liu, C.-Y., Huang, T.-T., Chu, P.-Y., Huang, C.-T., Lee, C.-H., Wang, W.-L., Lau, K.-Y., Tsai, W.-C., Chao, T.-I., Su, J.-C., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.114 · Cited by 40
Metadata
- Authors
- Győrffy, B., Surowiak, P., Budczies, J., & Lánczky, A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-18
- Volume
- 8
- Issue
- 12
- Pages
- e82241
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2126496132
- Cited by
- 1,760
- References
- 41
- FWCI
- 39.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.